BRPI0411945A - Antibodies and their uses - Google Patents

Antibodies and their uses

Info

Publication number
BRPI0411945A
BRPI0411945A BRPI0411945-2A BRPI0411945A BRPI0411945A BR PI0411945 A BRPI0411945 A BR PI0411945A BR PI0411945 A BRPI0411945 A BR PI0411945A BR PI0411945 A BRPI0411945 A BR PI0411945A
Authority
BR
Brazil
Prior art keywords
antibodies
metastasis
fragments
library
binding domain
Prior art date
Application number
BRPI0411945-2A
Other languages
Portuguese (pt)
Inventor
Daniel Plaksin
Avigdor Levanon
Esther Szanton
Yocheved Hagay
Rachel Ben-Levy
Yael Nisgav
Yariv Kanfi
Original Assignee
Bio Technology General Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Israel filed Critical Bio Technology General Israel
Publication of BRPI0411945A publication Critical patent/BRPI0411945A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"ANTICORPOS E SEUS USOS". A presente invenção provê anticorpos ou fragmentos dos mesmos que se ligam a células de câncer e é importante em fenómenos fisiológicos, tais como rolamento de células e metástase. Provêm-se também métodos terapêuticos e diagnósticos e composições que usam os referidos anticorpos e fragmentos dos mesmos. Os métodos e composições de acordo com a presente invenção podem ser usados para rastrear alvos de agentes terapêuticos e no diagnóstico, prognóstico e determinação do estágio, e na terapia de doenças como câncer, inclusive crescimento tumoral e metástase, leucemia, doença auto-imune, e doença inflamatória. Também se provê uma biblioteca de domínios de ligação de imunoglobulina tendo um domínio de ligação de antígeno diverso para ligação complementar, sendo que a biblioteca tem diversidade apenas em CDR3 de cadeia pesada."ANTIBODIES AND THEIR USES". The present invention provides antibodies or fragments thereof that bind to cancer cells and is important in physiological phenomena such as cell rolling and metastasis. Therapeutic and diagnostic methods and compositions using said antibodies and fragments thereof are also provided. The methods and compositions according to the present invention may be used to track targets of therapeutic agents and the diagnosis, prognosis and determination of stage, and in the treatment of diseases such as cancer, including tumor growth and metastasis, leukemia, autoimmune disease, and inflammatory disease. Also provided is an immunoglobulin binding domain library having a diverse antigen binding domain for complementary binding, the library having diversity in heavy chain CDR3 only.

BRPI0411945-2A 2003-06-30 2004-06-30 Antibodies and their uses BRPI0411945A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61123803A 2003-06-30 2003-06-30
PCT/US2004/021002 WO2005010153A2 (en) 2003-06-30 2004-06-30 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0411945A true BRPI0411945A (en) 2006-10-24

Family

ID=34103137

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411945-2A BRPI0411945A (en) 2003-06-30 2004-06-30 Antibodies and their uses

Country Status (11)

Country Link
EP (1) EP1649001A2 (en)
JP (1) JP2007528711A (en)
KR (1) KR20060106631A (en)
CN (1) CN101300021A (en)
AU (1) AU2004259406A1 (en)
BR (1) BRPI0411945A (en)
CA (1) CA2536644A1 (en)
IL (1) IL172510A0 (en)
MX (1) MXPA06000252A (en)
RU (1) RU2006102570A (en)
WO (1) WO2005010153A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714978A1 (en) * 2005-04-19 2006-10-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides useful for diagnosis and therapy of tumors
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
EP2161072A1 (en) * 2008-09-03 2010-03-10 Gambro Lundia AB High cut-off hemodialysis membranes for the treatment of chronic hemodialysis patients
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
ES2698606T3 (en) * 2012-01-20 2019-02-05 Genzyme Corp Anti-CXCR3 antibodies
EP4079324A1 (en) 2014-07-08 2022-10-26 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
BR112018013912A2 (en) * 2016-01-08 2018-12-18 Bioalliance C.V. tetravalent anti-psgl-1 antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1458500A (en) * 1998-10-30 2000-05-22 Jonathan L. Miller Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein IB alpha
CA2433225A1 (en) * 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Also Published As

Publication number Publication date
EP1649001A2 (en) 2006-04-26
KR20060106631A (en) 2006-10-12
JP2007528711A (en) 2007-10-18
MXPA06000252A (en) 2006-12-15
WO2005010153A3 (en) 2008-03-13
AU2004259406A1 (en) 2005-02-03
IL172510A0 (en) 2006-04-10
CA2536644A1 (en) 2005-02-03
CN101300021A (en) 2008-11-05
RU2006102570A (en) 2007-08-20
WO2005010153A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
Chai et al. LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression
Arcaini et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
ATE516047T1 (en) OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
Fritchie et al. Lipoblastomas presenting in older children and adults: analysis of 22 cases with identification of novel PLAG1 fusion partners
BRPI0408315A (en) isolated antibody, pharmaceutical composition, isolated nucleic acid, expression vector, host cell, methods of producing an antibody, generating an antibody or antigen binding fragment, regulating an immune response, treating or preventing a disorder associated with an immune cell in a patient to treat or prevent a hyperproliferative disorder in a patient, and diagnostic kit
ATE403001T1 (en) ANTIGEN BINDING FRAGMENTS SPECIFICALLY DETECTING CANCER CELLS, NUCLEOTIDES ENCODING THESE FRAGMENTS, AND THEIR USE IN PREVENTING AND DETECTING CANCER
Penna et al. Primary cross-resistance to BRAFV600E-, MEK1/2-and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
BRPI0410748A (en) improved cytotoxic agents comprising new maytansinoids
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
WO2007127936A3 (en) Methods and compositions for antibody therapy
BRPI0411945A (en) Antibodies and their uses
BR0213968A (en) Human antibodies that exhibit "mn" cell surface protein binding and cell adhesion neutralizing activity
BR112014029089A2 (en) antibody or antigen binding fragment thereof; polynucleotide encoding; compound; pharmaceutical composition / formulation; kit; use; in vitro method for reducing or inhibiting tg2 enzyme activity
Kincaid-Smith Malignant hypertension: mechanisms and management
Klumper et al. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia
BR0116764A (en) isolated molecules comprising epitopes containing sulfated moieties, antibodies to said epitopes and their uses
Jun et al. Expression of MET in alveolar soft part sarcoma
Touloumis et al. Retroperitoneal perivascular epithelioid cell tumours: A case report and review of literature
BR0312483A (en) Antibodies and their uses
ATE248189T1 (en) ANTIBODIES AGAINST VASP (VASODILATOR-STIMULATED PHOSPHOPROTEIN), HYBRIDOMA CELLS FOR THEIR OBTAINING, AND THEIR USE
AU2003242815A8 (en) Method for the characterisation of circulating tumour cells stemming from solid cancers
ATE477339T1 (en) COMPOSITIONS AND METHODS FOR PREDICTING THE OUTCOME OF TREATMENT
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
Lo et al. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.